-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Over 95% of gastric cancer is adenocarcinoma, and gastric cancer is characterized by high incidence and poor survival, making it the third most common cause of cancer death worldwide
.
In Europe, the overall 5-year survival rate is approximately 25%, and total or subtotal gastrectomy is the mainstay of treatment
Over 95% of gastric cancer is adenocarcinoma, and gastric cancer is characterized by high incidence and poor survival, making it the third most common cause of cancer death worldwide
statistics
Findings showed that of 2025 patients, 545 (26.
9%) used aspirin before gastrectomy
.
Aspirin use within 1 year before surgery did not reduce 5-year all-cause mortality (HR = 0.
Figure: The effect of aspirin use on survival
Therefore, the results of this study confirm that the use of low-dose aspirin does not improve long-term survival after gastrectomy for gastric adenocarcinoma, so aspirin should not be included in the routine treatment regimen
.
.
Original source:
Dag Holmberg.
Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma.
Leave a comment here